Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review

被引:6
|
作者
Mendoza-Pinto, Claudia [1 ]
Pirone, Carmelo [2 ]
van der Windt, Danielle A. [3 ]
Parker, Ben [4 ,5 ]
Bruce, Ian N. [4 ,6 ]
机构
[1] Mexican Inst Social Secur, Reg Gen Hosp CIBIOR 36, Syst Autoimmune Dis Res Unit, Puebla, Mexico
[2] Sapienza Univ Rome, Dept Internal Med, Med Specialties Rheumatol Unit, Rome, Italy
[3] Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England
[4] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Oxford Rd, Manchester, Lancs, England
[5] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Arthrit Res UK Ctr Epidemiol, Fac Biol Med & Hlth, Oxford Rd, Manchester, Lancs, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
Systemic lupus erythematosus; Mycophenolate mofetil; Systematic review; Prognosis; INTRAVENOUS CYCLOPHOSPHAMIDE; MAINTENANCE THERAPY; NEPHRITIS TREATMENT; INDUCTION TREATMENT; POLYMORPHISMS; DISEASE; ACID; PHARMACOKINETICS; AZATHIOPRINE; ASSOCIATION;
D O I
10.1016/j.semarthrit.2017.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We aimed to summarize the evidence examining factors that predict differential response to mycophenolate mofetil (MMF) in systemic lupus erythematosus (SLE). Methods: Systematic searches of randomized clinical trials (RCT) to identify predictors of the effects of MMF (moderators), and cohort studies to explore prognostic factors associated with MMF outcomes (response, relapse, or adverse events) were performed. Two reviewers independently assessed the methodological quality of RCTs using the Cochrane Collaboration risk of bias tool and cohort studies using the QUality In Prognosis Studies tool. The quality of subgroup analysis, providing evidence for moderation, was evaluated. The Grading of Recommendations Assessment, Development, and Evaluation working group approach summarized the quality of evidence (QoE), considering the risk of bias, imprecision, inconsistency, indirectness, and publication bias. Results: From 26 studies (13 from 7 RCTs and 13 cohort studies) we found low QoE evidence for Black/Hispanic race/ethnicity predicting better renal responses to MMF in lupus nephritis (LN) from one RCT. There was low QoE evidence from cohort studies that a higher baseline creatinine and membranous features on renal biopsy were associated with poorer responses in LN. There was very low QoE for other moderators or prognostic factors associated with MMF treatment outcomes. QoE from RCTs was affected by exploratory or insufficient evidence from subgroup analysis and in both study types high risk of bias, indirectness and imprecision also affected QoE. Conclusions: In SLE, evidence for predictors of response to MMF is limited and none can be recommended for use in routine clinical practice. Specific studies of predictors measured at baseline and during treatment are needed with a priori hypotheses based on preliminary evidence to date and with sufficient power to determine which factors can be employed in clinical decision making. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.
引用
收藏
页码:65 / 78
页数:14
相关论文
共 50 条
  • [1] CAN WE IDENTIFY WHO BENEFITS FROM MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS? A SYSTEMATIC REVIEW
    Mendoza Pinto, C.
    Pirone, C.
    Parker, B.
    Bruce, I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S115 - S115
  • [2] CAN WE IDENTIFY WHO BENEFITS FROM MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS? A SYSTEMATIC REVIEW
    Pinto, C. Mendoza
    Pirone, C.
    Parker, B.
    Bruce, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1045 - 1046
  • [3] Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
    Mendoza Pinto, Claudia
    Pirone, Carmelo
    Parker, Ben
    Bruce, Ian N.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review
    Mok, Cc
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2007, 36 (05) : 329 - 337
  • [5] Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature
    Fabrizio Conti
    Fulvia Ceccarelli
    Carlo Perricone
    Laura Massaro
    Enrica Cipriano
    Viviana Antonella Pacucci
    Simona Truglia
    Francesca Miranda
    Francesca Morello
    Cristiano Alessandri
    Francesca Romana Spinelli
    Guido Valesini
    Immunologic Research, 2014, 60 : 270 - 276
  • [6] Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature
    Conti, Fabrizio
    Ceccarelli, Fulvia
    Perricone, Carlo
    Massaro, Laura
    Cipriano, Enrica
    Pacucci, Viviana Antonella
    Truglia, Simona
    Miranda, Francesca
    Morello, Francesca
    Alessandri, Cristiano
    Spinelli, Francesca Romana
    Valesini, Guido
    IMMUNOLOGIC RESEARCH, 2014, 60 (2-3) : 270 - 276
  • [7] Reversible lymphoproliferative disorder in systemic lupus erythematosus treated with mycophenolate mofetil: A case report and literature review
    Tomoda, Hiroto
    Nakaya, Muneo
    Nakabeppu, Seiichiro
    Miyoshi, Hiroaki
    Ohshima, Koichi
    Miyoshi, Yuji
    LUPUS, 2025,
  • [8] The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry
    Jung, Ui Hong
    Kwak, Sang Gyu
    Choe, Jung-Yoon
    Lee, Shin-Seok
    Kim, Seong-Kyu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (27)
  • [9] Development of primary central nervous system lymphoma in a systemic lupus erythematosus patient after treatment with mycophenolate mofetil and review of the literature
    Balci, M. A.
    Pamuk, G. E.
    Unlu, E.
    Usta, U.
    Pamuk, O. N.
    LUPUS, 2017, 26 (11) : 1224 - 1227
  • [10] PROGRESSION FROM CUTANEOUS TO SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC LITERATURE REVIEW
    Singh, B.
    Kaur, N.
    Attri, S.
    Kaur, G.
    VALUE IN HEALTH, 2023, 26 (12) : S220 - S220